Effects of HMG-CoA Reductase Inhibitors on Coagulation and Fibrinolysis Processes

被引：0
作者：
Robert Krysiak
Boguslaw Okopień
Zbigniew S. Herman
机构：
[1] Medical University of Silesia,Department of Clinical Pharmacology
来源：
Drugs | 2003年 / 63卷
关键词：
Simvastatin; Atorvastatin; Pravastatin; Human Umbilical Vein Endothelial Cell; Tissue Factor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Recent large clinical trials have demonstrated that HMG-CoA reductase inhibitors, or statins, markedly reduce morbidity and mortality when used in the primary and secondary prevention of cardiovascular disease. It has been established that the benefits of statin therapy in cardiovascular disease can be explained not only by the lipid-lowering potential of statins but also by nonlipid-related mechanisms (so-called ‘pleiotropic effects’) that contribute to the positive effect of statins on the incidence of cardiovascular events.
引用
收藏
页码：1821 / 1854
页数：33
相关论文
共 419 条
[1]  
Shepherd J(1994)Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study Group Lancet 344 1383-9
[2]  
Cobbe SM(1995)Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia West of Scotland Coronary Prevention Study Group. N Engl J Med 333 1301-7
[3]  
Ford I(1996)The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 1001-9
[4]  
Sacks FM(1998)Are there potential non-lipid-lowering uses of statins? Drugs 56 517-22
[5]  
Pfeffer MA(2000)Non-lipid-related effects of statins Ann Med 32 164-76
[6]  
Moye LA(2000)Effects of statins on vascular wall: vasomotoric function, inflammation, and plaque stability Cardiovasc Res 47 648-57
[7]  
Wheeler DC(2001)Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy Am J Cardiovasc Drugs 1 411-20
[8]  
Bellosta S(1995)Hemostasis and atherosclerosis Can J Cardiol 11 29C-34C
[9]  
Ferri N(1998)Classical risk factors and emerging elements in the risk profile for coronary artery disease Eur Heart J 19 A53-61
[10]  
Bernini F(2001)Hemostatic risk factors for atherothrombotic disease: an epidemiologic view Thromb Haemost 86 366-73
12345678910